MedTrace Logo

Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia

NCT00442676 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-03-13

No results posted yet for this study

Summary

Preeclampsia is a hypertensive disorder of pregnancy and a leading cause of fetal and maternal morbidity and mortality. Recent findings indicate preeclampsia is an inflammatory disorder associated with increased expression of COX-2. This study will test the hypothesis that treatment of women with a COX-2 inhibitor, celecoxib, will stop the inflammatory process and reverse symptoms of preeclampsia.

Conditions

Interventions

DRUG

Celecoxib

Capsule, 200 mg/day until 32 weeks of gestation

DRUG

Placebo

Gelatin capsules of lactose

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Scott W Walsh, PhD · Virginia Commonwealth University

  • Susan M Lanni, MD · Virginia Commonwealth University

  • Fidelma B Rigby, MD · Virginia Commonwealth University

  • Nicole W Karjane, MD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00442676 on ClinicalTrials.gov